Medtronic plc has announced key board appointments and governance initiatives designed to advance strategic priorities and enhance shareholder value, following “constructive engagement” with activist hedge fund firm Elliott Management.
In a press statement, the firm announced its Board has appointed John Groetelaars and William Jellison as independent directors. Both bring deep medical technology and operational expertise, and will serve on newly formed Growth and Operating Committees, chaired by CEO Geoff Martha. The committees aim to sharpen focus on portfolio management, operational efficiency, margin expansion, and capital allocation – including the previously announced separation of Medtronic’s Diabetes business.
The company plans to host an Investor Day in 2026 to provide updates on these initiatives.
Elliott Partner Marc Steinberg said the firm’s investment in Medtronic reflects confidence in the company’s potential for accelerated growth, operational improvement, and strategic clarity. “Today’s announcements – including the addition of new directors with deep medical technology experience and the formation of two focused Board committees – are the right steps towards realising Medtronic’s potential,” he said. “We look forward to continuing our constructive partnership with Geoff Martha and the Board and to working closely together to realise this unique value-creation opportunity.”
